FGF2 Reporter Cell Assay for High-Throughput Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for high-throughput detection of FGF2 secretion and signaling, which is crucial for understanding its role in tumor therapy and other biological processes, as existing systems are not suitable for detecting FGF2 effectively.
Innovation Solution
A method involving target cells sensitive to FGF2, expressing a first fluorescent reporter, which can be co-incubated with FGF2-secreting cells or compounds, allowing for the identification of FGF2 modulating compounds by monitoring fluorescence changes indicative of proliferation and apoptosis, using a second fluorescent reporter for apoptotic cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cancer derived cell lines expressing eGFP are used for high throughput analysis, then flow cytometry analysis of cell cycle profile and apoptosis can be performed, but the system is not appropriate for detecting FGF2 secretion
Solution Approach 1:
The patent introduces a reporter cell line that serves as an intermediary system. These cells contain a promoter responsive to FGF2 that drives expression of a reporter gene (such as luciferase or GFP). When FGF2 is secreted by tumor cells, it binds to receptors on the reporter cells, activating the promoter and producing a measurable signal. This intermediary system enables detection of FGF2 secretion while maintaining high throughput capabilities through automated imaging or flow cytometry.
2Productivity
If a constitutive CMV promotor driven eGFP is used in lymph node metastasis derived cell line, then high throughput system can be established, but the system is not suitable for detecting FGF2 secretion
Solution Approach 1:
The patent modifies the promoter parameter from a constitutive CMV promoter to an FGF2-responsive promoter. This parameter change allows the reporter gene expression to be dynamically regulated by FGF2 levels. The responsive promoter contains specific binding sites for transcription factors that are activated by FGF2 signaling, thereby coupling reporter expression directly to FGF2 secretion levels and enabling precise measurement.
3Measurement precision
If simplified direct co-culture system with eGFP expressing pancreatic cancer cell lines is used, then populations of cancer cells can be quantified, but the system cannot detect FGF2 secretion
Solution Approach 1:
The patent merges two functional capabilities into a single reporter cell line: (1) the ability to sense FGF2 through FGF2-responsive promoter elements, and (2) the ability to provide a quantifiable signal through reporter gene expression. This combined system allows simultaneous quantification of cancer cell populations and detection of FGF2 secretion in the same co-culture assay, achieving both objectives in one versatile platform.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the identification of compounds affecting FGF2 secretion and signaling, providing a tool for high-throughput screening and understanding FGF2's role in cell proliferation and apoptosis, suitable for applications in tumor therapy and other cellular processes.
Implementation Method 1
employing a first fluorescent reporter and, optionally, a second fluorescent reporter
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a method for the identification of compounds modulating the biological activity of FGF2, the method comprising the use of target cells sensitive to the presence of FGF2 by obstructing proliferation, wherein the target cells constitutively express a first reporter in the nucleus of living target cells.